Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
Irruption of decitabine and azacitidine has led to profound changes in the upfront management of older acute myeloid leukaemia (AML). However, they have not been directly compared in a randomised clinical trial. In addition, there are no studies comparing the optimal treatment schedule of each drug...
Saved in:
Main Authors: | Miriam Saiz-Rodríguez, Jorge Labrador, Beatriz Cuevas, David Martínez-Cuadrón, Verónica Campuzano, Raquel Alcaraz, Isabel Cano, Miguel A. Sanz, Pau Montesinos |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c2d01b7cf4a649cfac3c23bf43700bdb |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
by: Briot T, et al.
Published: (2017) -
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
by: Ritchie EK
Published: (2012) -
The first case of acute myeloid leukaemia/myeloid sarcoma with cytokeratin expression on blasts diagnosed on urine specimen
by: Claire Comerford, et al.
Published: (2021) -
Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia
by: Julien M. P. Grenier, et al.
Published: (2021) -
Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
by: Carlo Pescia, et al.
Published: (2021)